program. It is not clear how long these physicians had been using EHRs prior to the study period. Many meaningful users will be implementing EHRs for the first time because of this policy. Studies on applications for e-prescribing have shown that, even 2 years after implementation, physicians are still on a learning curve, improving their care.
ducted too soon after implementation may not find an effect, even if one exists.
A third issue is the reliability of electronic reporting of quality measures. Previous studies have shown that automated electronic algorithms for extracting quality data from EHRs are not always accurate. 6 Automated reporting can underestimate or overestimate rates of recommended care because it tends to capture only those elements that are structured fields (eg, drop-down menus, check boxes, or other similar fields) and not those elements that are documented as free text. These challenges can be addressed, with both more nuanced specifications for automated reporting and more structured documentation of the care provided. A fourth issue is the importance of understanding how physicians actually use EHRs to achieve MU and how that usage affects medical decision-making. 7 The study by Samal et al 1 and other similar studies could be strengthened by measuring not only achievement of MU as the predictor variable but actual usage of EHRs as well. Without measurement of actual usage, any apparent association between achievement of MU and quality could be confounded by unmeasured variables. Finally, MU is being rolled out in stages, and each stage is designed to become more complex and more difficult to achieve than the previous one. Stage 1 MU, which the study by Samal et al 1 examined, began in 2011 and involves attesting to the use of EHRs to capture clinical data electronically. For example, health care providers attest to measures such as recording vital signs in the EHR for at least 50% of patients. Stage 2 begins in 2014 and raises the thresholds for many measures (eg, record vital signs for at least 80% of patients). Stage 2 also promotes electronic health information exchange and carries the option of reporting performance on quality measures electronically, among other goals. Stage 3 is expected to begin in 2017 and to reward providers for not only reporting the level of quality provided but for improving on that level as well. Thus, the full effects of MU on quality may not be measurable until stages 2 or 3.
In conclusion, the MU program is unprecedented, both in terms of the magnitude of the financial incentives and in the degree to which it is shaping day-to-day clinical care. It is not clear whether MU will improve quality, but it is also not clear that quality would be improved without adoption and use of EHRs. Electronic health records are powerful tools with which to manage populations of patients, and there are few ways to manage populations of patients with paper records. Quality is also only 1 relevant outcome; measuring the value of health care, which incorporates both quality and cost, is extremely important. The need to adopt and use EHRs is also leading to many secondary effects in health care delivery, including the merging of small practices that do not have enough resources to adopt EHRs on their own. Ongoing evaluation is critical to 
Use of Mechanical Ventilation by Patients With and Without Dementia, 2001 Through 2011
Increasing demand for US critical care resources, including beds, intensivists, and invasive mechanical ventilation (IMV), 1,2 has placed substantial strain on the critical care system. Since 2000, elderly patients treated in the intensive care unit have received higher intensity care (and have experienced lower mortality rates) than historical cohorts. 3 Yet certain populations of elderly patients exposed to intensive care experience substantial long-term adverse effects, including functional decline and excess mortality. Patients with dementia receiving IMV, for example, are at high risk for delirium, which confers a 3.2-fold increased risk of 6-month mortality.
4
The increasing use of aggressive therapies suggests that demand for IMV in elderly populations will increase in the future, both among patients that are likely to benefit and among those with terminal illness. We examined temporal trends in IMV use by older patients with and without dementia and projected future use.
Methods | Data for this investigation came from the US Nationwide Inpatient Sample (NIS). Because the NIS is a public, deidentified data set, the Baystate Medical Center institutional review board has declared that research using the NIS does not meet regulatory criteria for human subjects research. (Table) . The prevalence of dementia diagnoses increased significantly (P < .001), ex- Discussion | The use of IMV by populations 65 years or older is expected to double between 2001 and 2020, and growth in hospitalizations for patients receiving IMV with an ICD-9-CM diagnosis of dementia is outpacing, by a factor of 4, those for patients receiving IMV without this diagnosis. These projected IMV numbers are consistent with published data.
5,6
The use of ICD-9-CM codes to identify patients with dementia may be limited by poor sensitivity and lack of information about disease severity. Although better recognition of dementia among hospital providers may have contributed to some of the increase that we observed, the results of this study still have important implications for critical care resource planning. Given projected demand for IMV in the next 10 years, physicians and hospital administrators, already working in a strained system, face a potential crisis unless the critical care system is expanded or changes are made to temper current trends.
Efforts should therefore be made to promote earlier discussions about goals of care in elderly patients with endstage terminal illnesses. This is most important for the subpopulations of patients (eg, frail elders older than 85 years, patients with end-stage dementia) who are least likely to benefit from IMV and at highest risk for worsening cognitive impairment and death.
